Lilly acquires Kelonia Therapeutics

Eli Lilly has agreed to acquire Kelonia Therapeutics in a deal valued at up to $7 billion. This transaction positions Lilly within the evolving landscape of cell therapy, focusing on Kelonia’s in vivo gene therapy platform. The acquisition underscores a strategic push to make CAR-T treatments more accessible by overcoming existing logistical and cost barriers.

Under the terms, Eli Lilly will pay $3.25 billion upfront, with contingent milestone payments potentially driving the total deal value to $7 billion. These milestones are tied to specific clinical, regulatory, and commercial achievements. The transaction is expected to finalize in the second half of 2026, pending typical regulatory approvals. Kelonia's shareholders stand to gain significantly from these milestone accomplishments. Lilly has been active in enhancing its oncology portfolio, following similar transactions, including a potential $7.8 billion acquisition of Centessa Pharmaceuticals and a $2.75 billion collaboration for AI-driven drug discovery with Insilico Medicine.

Kelonia Therapeutics brings a proprietary technology, the in vivo gene placement system (iGPS), which uses engineered lentiviral particles to modify T-cells directly within the patient. This approach could circumvent the traditional CAR-T process, which involves removing, engineering, and reinfusing T-cells and often proves cumbersome and costly. Kelonia's lead program, KLN-1010, targets multiple myeloma by producing anti-BCMA CAR-T cells within the body. Early Phase I clinical data indicates promising tolerability and efficacy, suggesting a potential breakthrough for treatments of this kind.

This acquisition highlights Lilly's commitment to redefining the current treatment landscape by leveraging Kelonia’s platform to introduce a more simplified, cost-effective alternative to existing therapies. The move aligns with broader industry trends where major pharmaceutical companies are seeking to expand cell and gene therapy capabilities to enhance patient access and streamline treatment processes.

As the sector pivots towards in vivo methods, this acquisition by Lilly may prompt competitors to reconsider their strategies in developing similar technologies or pursuing collaborative ventures. Prospective regulatory approvals and successful clinical milestones will be crucial for closing the deal and realizing its full potential benefits for both Lilly and the broader healthcare market.